Lidia Corrêa Parra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lidia Corrêa Parra has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bruna Costa Zorzanelli
Universidade Estácio de Sá
1 shared publication - Caroline Rodrigues Chaves dos Reis
Fundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós‐Graduação em Pesquisa Translacional em Fármacos e Medicamentos Rio de Janeiro RJ Brazil
1 shared publication - Guilber Valério Chaves Moura de Souza
Fundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Laboratório de Síntese de Fármacos (LASFAR) Rio de Janeiro RJ Brazil
1 shared publication - Hellen Valério Chaves Moura de Souza
Fundação Oswaldo Cruz, Fiocruz, Instituto de Tecnologia em Fármacos, Programa de Pós‐Graduação em Pesquisa Translacional em Fármacos e Medicamentos Rio de Janeiro RJ Brazil
1 shared publication - Lucas Villas Bôas Hoelz
Fundação Oswaldo Cruz
1 shared publication - Nubia Boechat
FIOCRUZ
1 shared publication
Latest Publications
- Open Access
- 14 June 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (6) , e70340
Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.
- 14 June 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (6) , e70340
Open AccessCruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.